Antineoplastic agents 1998

This review will focus on the most recent patent-disclosed advances in iden tifying new potent drugs for cancer chemotherapy since the subject was last discussed in this journal in 1997, with the exception of fields that have been subsequently covered by other more focused reviews in the same journal .In particular we will summarise developments in the design and biochemical and pharmacological evaluation of novel antineoplastic agents belonging to the following classes: natural and fermentation products, DNA-targeted cyt otoxic compounds, drugs for photodynamic therapy, non-taxane antimicrotubul e agents, apoptosis modulators, enzymatic inhibitors, hormonal agents, mult i-drug resistance reverters and antimetastatic drugs.